121669-69-0

Basic information

• Product Name: 4-Methyl-1H-pyrazole-1-carboxylic acid 1,1-dimethylethyl ester
• Synonyms: 1-tert-Butoxycarbonyl-4-methylpyrazole;4-Methyl-1H-pyrazole-1-carboxylic acid 1,1-dimethylethyl ester;4-Methylpyrazole-1-carboxylic acid tert-butyl ester;tert-butyl 4-methyl-1H-pyrazole-1-carboxylate;tert-butyl 4-methyl-1H-pyrazole-1-carboxylate(WXC04541)
• CAS NO: 121669-69-0
• Molecular Formula: C9H14N2O2
• Molecular Weight: 182.21966
• Mol File: 121669-69-0.mol

Chemical Properties

• Boiling Point: 255℃
• Flash Point: 108℃
• Appearance: /
• Density: 1.07
• CAS DataBase Reference: 4-Methyl-1H-pyrazole-1-carboxylic acid 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methyl-1H-pyrazole-1-carboxylic acid 1,1-dimethylethyl ester(121669-69-0)
• EPA Substance Registry System: 4-Methyl-1H-pyrazole-1-carboxylic acid 1,1-dimethylethyl ester(121669-69-0)

Safety Data

• Hazardous Substances Data: 121669-69-0(Hazardous Substances Data)

Upstream product

• 7554-65-6 4-methyl-1H-pyrazole 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 530144-72-0 tert-butyl 4-(bromomethyl)-1H-pyrazole-1-carboxylate 

Relevant articles and documents

SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5

Disclosed are compounds having structural formula I, and related salts and pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating diseases and conditions such as kidney disease, kidney failure, kidney stones, or polycystic kidney disease, using the compounds of formula (I), and related salts and pharmaceutical compositions.

PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS

Disclosed in the present application is a compound of formula (I) as defined herein as well as a pharmaceutical composition comprising said compound. Further disclosed in the present application is the use of such pharmaceutical compositions for treating diseases, namely inter alia for use in the treatment of cancer, metabolic, inflammatory, autoimmune and viral diseases. The compounds disclosed herein are inhibitors of MNK1 and/or MNK2 kinases.

PROBES FOR IMAGING HUNTINGTIN PROTEIN

Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.

NOVEL ANTIVIRAL PYRROLOPYRIDINE DERIVATIVE AND A PRODUCTION METHOD FOR SAME

The present invention relates to a pyrrolopyridine derivative represented by the Chemical Formula I, and a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and relates to an antiviral composition including the same as an active ingredient. The compound of the Chemical Formula I has excellent antiviral activity and selectivity for wild type and resistant HIV-1, and thereby is useful as a therapeutic agent for acquired immune deficiency syndrome (AIDS).

CARBACEPHEM BETA-LACTAM ANTIBIOTICS

Carbacephem β-lactam antibiotics having structure (I) are disclosed, including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar2, X, R1 and R2 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.

HETEROCYCLIC ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are heteroaryl compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the heteroaryl compounds described. Also described herein are methods of using such an

SUBSTITUTED PYRIDINONES

Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.

NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF

A benzophenone derivative represented by the following formula: whereinR1 represents, for example, an optionally substituted heterocyclic group, or a substituted phenyl group; Z represents, for example, an alkylene group; R2 represents, for example, a carboxyl group optionally protected with alkyl;R3 represents, for example, an optionally protected hydroxyl group; R4 represents, for example, an optionally substituted cycloalkyloxy group; and R5 represents, for example, a hydrogen atom, ???or a salt thereof has anti-arthritic activity, inhibits bone destruction caused by arthritis, and provides high safety and excellent pharmacokinetics and thus is useful as therapeutic agent for arthritis. These compounds have inhibitory effect on AP-1 activity and are useful as preventive or therapeutic agent for diseases in which excessive expression of AP-1 is involved.